title: Expression of chloride channel protein CLC-3 in patients with allergic rhinitis: effect of topical corticosteroid treatment.
abstract: OBJECTIVE
  To determine whether the chloride channel protein CLC-3 is upregulated in patients with allergic rhinitis (AR) and whether topical corticosteroid treatment decreases the expression of CLC-3.
  
  
  METHODS
  Histologic study.
  
  
  METHODS
  Academic research.
  
  
  METHODS
  Eighteen patients with AR were included in the study.
  
  
  METHODS
  Expression of CLC-3 was detected by immunohistochemistry and by reverse transcription-polymerase chain reaction before and at 4 weeks after treatment with the topical corticosteroid mometasone furoate.
  
  
  RESULTS
  Strong CLC-3 expression was detected in epithelium and in submucosal glands. An increased presence of CLC-3 was demonstrated in nasal mucosa compared with that in normal nasal tissue. A statistically significant difference in CLC-3 gene expression level was found in nasal tissues before vs at 4 weeks after treatment with mometasone.
  
  
  CONCLUSIONS
  CLC-3 may have a role in modulating the pathogenesis of AR. Decreased expression of CLC-3 may be the mechanism of action of corticosteroid treatment in controlling AR.
authors.affiliation: Otorhinolaryngology Hospital, First Affiliated Hospital, and Otorhinolaryngology Institute, Sun Yat-sen University, Guangzhou 510080, China.
authors.forename: Huabin
authors.initials: H
authors.lastname: Li
authors.forename: Weiping
authors.initials: W
authors.lastname: Wen
authors.forename: Lei
authors.initials: L
authors.lastname: Cheng
authors.forename: Jianbo
authors.initials: J
authors.lastname: Shi
authors.forename: Hongyan
authors.initials: H
authors.lastname: Jiang
authors.forename: Yun
authors.initials: Y
authors.lastname: Oh
authors.forename: Geng
authors.initials: G
authors.lastname: Xu
mesh_terms: D000287:Administration, Topical; D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D018118:Chloride Channels / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D009297:Nasal Mucosa / Q000378:metabolism*; D011244:Pregnadienediols / Q000008:administration & dosage*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000378:metabolism*; D018709:Statistics, Nonparametric; D015854:Up-Regulation
chemical_list: D018926:Anti-Allergic Agents; D018118:Chloride Channels; C115376:ClC-3 channel; D011244:Pregnadienediols; D000068656:Mometasone Furoate